DRR168542
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.510
- INTERFERON_GAMMA_RESPONSE+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- ADIPOGENESIS+0.380
- ALLOGRAFT_REJECTION+0.350
- MYC_TARGETS_V2+0.330
- IL6_JAK_STAT3_SIGNALING+0.320
- DNA_REPAIR+0.300
- PROTEIN_SECRETION+0.300
Top 10 suppressed
- E2F_TARGETS-0.460
- SPERMATOGENESIS-0.390
- G2M_CHECKPOINT-0.380
- PANCREAS_BETA_CELLS-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.210
- KRAS_SIGNALING_DN-0.200
- MYOGENESIS-0.170
- CHOLESTEROL_HOMEOSTASIS-0.130
- HEDGEHOG_SIGNALING-0.120
- APICAL_SURFACE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13311160 | — | — | 0.872 |
| 2 | MNG415 | — | — | 0.817 |
| 3 | MNG1167 | — | — | 0.801 |
| 4 | BS_JK0VPG1T | Schwannoma | — | 0.800 |
| 5 | BS_CQEETJ66 | Schwannoma | — | 0.798 |
| 6 | DRR168598 | — | — | 0.788 |
| 7 | BS_HBJZR69P | Schwannoma | — | 0.786 |
| 8 | BS_W72364MN | Meningioma | — | 0.780 |
| 9 | MNG634 | — | — | 0.780 |
| 10 | 3BCD8BE5-753D-43EF-B830-EA4356620A5C | — | — | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |